Introduction {#sec1-1}
============

Breast cancer (BC)is the leading cause of cancer death among females (Jemal et al., 2011; Guo et al., 2012) and its development is a multifactorial complex process influenced by multiple genetic variants and environmental factors (Nathanson et al.,2001; Guo et al., 2012). Estrogen hormones affect the cell growth and proliferation during breast carcinogenesis and metabolized by several enzyme including COMT, which metabolized itinto biologically non-hazardous methoxyestrogens(Onay et al., 2008). COMT enzyme are found in two isoforms in the cells: a cytoplasmic smaller protein (S-COMT; 221 aa) and a membrane-bound longer protein (MB-COMT 271 aa) (Tenhunen et al. 1994).

COMT gene is present at chromosome 22q11.1 and a single base pair G\--\>A substitution at position 472(G472A/Val158Met)in exon 4, results in substitution of valine by methionine in COMT enzyme (Lotta et al., 1995; Lachman et al., 1996). The two alleles are referred to as Val(G) and Met(A). Val allele encodes the thermostable high activity COMT enzyme and Met allele encodes the thermolabile low activity COMT enzyme (Spielman and Weinshilboum, 1981; Lotta et al., 1995; Nobile et al., 2010). Both the alleles are co-dominant, i.e. heterozygous individuals (Val/Met) have an intermediate level of COMT activity (Lotta et al., 1995). The frequency of the mutant Met allele vary greatly among the populations studied, frequency of Met allele is reported as 0.56 in American (Vandenbergh et al., 1997), 0.5 in European (Kunugi et al., 1997), and 0.27 in Asian (Chen et al., 1997)populations. COMT gene Val158Met is a clinically functional polymorphism, and reported as risk factor for several disorders/diseases-schizophrenia (Kayahan et al., 2013), attention-deficit hyperactivity disorder (Retz et al., 2008), autism (Gadow et al., 2009), drug abuse (Vinkers et al., 2013), posttraumatic stress disorder (Valente et al., 2011), and cancer (Omrani et al., 2009) etc.

COMT enzyme metabolized estrogen and its carcinogenic derivatives, hence study of COMT gene polymorphisms as risk for cancer is of particular interest. In the past years, several case-control studies have been investigated the association between COMT Val158Met polymorphisms and breast cancer susceptibility (Kocabas et al.,2002; Wen et al., 2005;Chang et al.,2006; Wang et al., 2010; Naushad et al., 2011;Lajin et al.,2013). However, individual study limitations contributed to divergent conclusions among them. Aim of the present meta-analysis was to find out the relationship between COMT Val158Met polymorphism and breast cancer risk in Asian population.

Materials and Methods {#sec1-2}
=====================

Data Sources, Search Strategy, and Selection Criteria {#sec2-1}
-----------------------------------------------------

The articles for the present meta-analysis were retrieved by searching the PubMed (<http://www.ncbi.nlm.nih.gov/pubmed>), Google Scholar (<http://scholar.google.com>), Science Direct (<http://www.sciencedirect.com>), and Springer Link (<http://link.springer.com>)databases up to March, 2016, using the keywords "breast cancer", "Val158Met", "Catechol-O-methyltransferase" and "COMT".

Article selection for the present meta-analysis used the following inclusion criteria:(i) study should be case-control; (ii) sufficient genotype/allele data to calculate the odds ratios (ORs) with 95% confidence intervals should be reported (CIs). Exclusion criteria were the following: (i) only cases were analyzed; (ii) editorial, review articles etc.;(iii)not sufficient data/information to calculate odds ratio with 95%CI were reported; (v) other cancer type were investigated in the study and (vi) non-Asian breast cancer cases were investigated.

Data Extraction and Quality Assessment {#sec2-2}
--------------------------------------

Data extraction and quality assessment were performed by two investigators (PK and UY). From each included relevant article, the following data were extracted: the family name of first author, the publication year, journal name, country name, the study design i.e. source of controls, the sample size, and the genotype distribution for the participants. Method of Guo et al., (2012) was adopted for study quality assessment. The quality scores ranged from 0 to 10 and studies with score \<5 was defined as low quality, and studies with score ≥7 was defined as high quality.

Statistical Analysis {#sec2-3}
--------------------

Odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were used as the measure of association between the COMT Val158Met polymorphism and breast cancer susceptibility. Data were pooled using the fixed effect (Mantel and Haenszel,1959) and random effect (DerSimonian and Laird, 1987) methods. p\<0.05 was considered as statistically significant. Heterogeneity between conducted by X2-based Q-test and quantified by I2 (Cochran,1954; Higgins and Thompson, 2002; Whitehead, 2002). For this polymorphism all five genetic models, the additive model (Met vs. Val; A v.s G), homozygote model (Met/Met vs.Val/Val; AA vs. GG), heterozygote model (Val/Met vs Val/Val; GA vs GG), dominant model (Met/Met+Val/Met vs Val/Val; AA+GA vs GG) and recessive model (Met/Met vs Val/Met + Val/Val; AAvs GA+GG) were chosen to calculate the pooled ORs. x^2^ test was done to evaluate Hardy-Weinberg Equilibrium (HWE) for control subjects in each study. Publication bias was assessed by Begg's funnel plot and Egger's linear regression test (Egger et al., 1997). All statistical analyses were performed by Open Meta-Analyst (Wallace et al., 2013).

Results {#sec1-3}
=======

Literature Search {#sec2-4}
-----------------

Initial search of four databases, 203 articles were retrieved, but 141 articles did not meet the inclusion criteria after reviewing abstract. The excluded articles include results of drug treatments of breast cancer, book chapter, comments, editorials, reviews, meta-analysis and articles investigated other genes. Out of remaining sixty two articles, we also excluded thirty nine articles, in which investigated subjects were not from Asian population. After applying inclusion/exclusion criteria, total 23articles ([Figure 1](#F1){ref-type="fig"}) were suitable for the present meta-analysis (Huang et al., 1999; Hamajima et al., 2001; Yim et al., 2001; Kocabas et al., 2002; Tan et al., 2003; Wu et al., 2003; Sazci et al., 2004; Cheng et al., 2005; Lin SC et al., 2005; Lin WY et al., 2005; Wen et al., 2005; Chang et al., 2006; Akisik and Dalay, 2007; Fan et al., 2007; Hu et al., 2007; Sangrajrang et al., 2009; Yadav et al., 2009; Syamala et al., 2010; Xu et al., 2010; Naushad et al., 2011; Wang et al., 2011; Lajin et al., 2013; Li et al., 2013). These studies were published between 1999 to 2013. One author (Syamala et al.,2010) studied sporadic and familial cases both and reported separately in their article, so we also included both groups of data as separate studies. Wu et al., 2003 reported three individual populations (Chinese, Japanese and Filipino) so we included them as three separate studies. Hence total twenty six studies were included in the present meta-analysis. Characteristics of all the included studies were given in [Table 1](#T1){ref-type="table"}. These studies were carried out in different countries-China (Huang et al., 1999; Tan et al.,2003; Wu et al., 2003; Cheng et al., 2005; Lin WY et al.,2005; Wen et al., 2005; Chang et al., 2006; Fan et al., 2007; Hu et al., 2007; Xu et al., 2010; Wang et al., 2011; Li et al., 2013), India (Yadav et al., 2009; Syamala et al., 2010; Naushad et al., 2011), Japan (Hamajima et al., 2001; Yim et al., 2001; Wu et al., 2003), Philippines (Wu et al., 2003), Syria (Lajin et al., 2013), Taiwan (Lin SC et al., 2005), Thailand (Sangrajrang et al., 2009), Turkey (Kocabas et al., 2002; Sazci et al., 2004; Akisik and Dalay, 2007).

![Flow Diagram of Study Search and Selection Process](APJCP-18-1243-g001){#F1}

###### 

Characteristics of Twenty Four Studies Included in the Present Meta-Analysis

  Study                      Country    Source of Control   Menopausal Status   Case/Control   Case   Genotypes        Control   Genotypes          HWE       Quality Score
  -------------------------- ---------- ------------------- ------------------- -------------- ------ ----------- ---- --------- ----------- ------ --------- ---------------
  Huang et al., 1999         China      HB                  Pre-,Post-          113/124        66     35          12   65        55          4      0.06      8.5
  Hamajima et al., 2001      Japan      HB                  Pre-,Post-          150/165        60     72          18   79        63          23     0.08      8.5
  Yim et al., 2001           Japan      HB                  Pre-,Post-          163/163        81     79          3    101       46          16     0.004\*   5.5
  Kocabas et al., 2002       Turkey     HB                  Pre-,Post-          84/103         28     42          14   35        55          13     0.23      5.5
  Tan et al., 2003           China      HB                  Pre-,Post-          250/250        121    103         26   132       105         13     0.17      
  Wu et al., 2003            China      PB                  Mixed               178/199        97     67          14   106       78          15     0.9       8.0
  Japan                      PB         Mixed               193/197             88             89     16          86   87        24          0.78             
  Philippines                PB         Mixed               218/166             143            57     18          90   64        12          0.89             
  Sazci et al., 2004         Turkey     PB                  Pre-                130/224        33     69          28   62        146         16     0.00\*    6.0
  Cheng et al., 2005         China      HB                  Mixed               469/740        237    197         35   420       262         58     0.06      7.5
  Lin WY et al., 2005        China      PB                  Mixed               87/341         51     31          5    190       133         18     0.39      7.5
  Lin SC et al., 2005        Taiwan     PB                  Mixed               99/366         58     35          6    205       138         23     0.97      6.5
  Wen et al., 2005           China      PB                  Pre-,Post-          1120/1191      612    425         83   628       470         93     0.69      9.5
  Chang et al., 2006         China      HB                  Mixed               189/320        103    77          9    131       159         30     0.06      6.5
  Akisik et al., 2007        Turkey     NR                  Mixed               114/108        29     59          26   34        53          21     0.96      3.0
  Fan et al., 2007           China      NR                  Mixed               200/100        96     75          29   51        44          5      0.24      7.5
  Hu et al., 2007            China      HB                  Pre-,Post-          112/110        65     36          11   66        41          3      0.25      6.5
  Sangrajrang et al., 2009   Thailand   HB                  Mixed               565/486        290    233         42   266       190         30     0.6       9.0
  Yadav et al., 2009         India      HB                  Pre-,Post-          59/99          23     30          6    32        53          14     0.28      7.0
  Syamala et al., 2010a      India      PB                  Mixed               140 /367       48     64          28   138       164         65     0.18      7.0
  Syamala et al., 2010b      India      PB                  Mixed               219 / 367      74     104         41   138       164         65     0.18      7.0
  Xu et al., 2010            China      NR                  Mixed               140/122        60     42          38   68        44          10     0.45      6.5
  Naushad et al., 2011       India      HB                  Mixed               212/233        71     94          47   115       103         15     0.2       6.0
  Wang et al., 2011          China      PB                  Pre-,Post-          400/400        187    145         68   208       156         36     0.39      7.0
  Lajin et al., 2013         Syria      PB                  Pre-,Post-          135/107        34     70          31   23        54          30     0.88      6.5
  Li et al., 2013            China      HB                  Mixed               120/120        58     45          17   73        42          5      0.73      7.0

HB, hospital-based; PB, population-based; NR, not reported; Pre, premenopausal; Post, postmenopausal

Study Characteristics {#sec2-5}
---------------------

All twenty six studies were published between 1999 (Huang et al., 1999) to 2013 (Li et al., 2013). Smallest sample size of cases studied was 59 (Yadav et al., 2009) and largest sample size was 1,120 (Wen et al., 2005). In twelve studies, age and sex matched controls are selected from hospital and in eleven studies controls were selected from population. In three studies source of controls were not given. Control population of two studies (Yim et al., 2001; Sazciet al., 2004) were not in HWE. In eleven studies, selected patients were of premenopausal state and in ten studies cases were at postmenopausal state. In remaining studies menopausal status of patients was not given. Total cases were 5,971 with GG (2,844), GA (2,432) and AA (695) genotypes and controls were 7,253 with GG (3,584), GA (2,998) and AA (671) genotypes. In total cases, genotypes percentage of GG, GA and AA were 47.63%, 40.73% and 11.64% respectively. In controls, genotypes percentage of GG, GA and AA were 49.41, 41.34% and 9.25%respectively. Out of twenty six studies, six studies did not report any association between COMT Val158Met and breast cancer (Lin SC et al., 2005; Lin WY et al., 2005;Wen et al., 2005; Chang et al., 2006; Yadav et al., 2009; Lajin et al., 2013).

Meta-analysis {#sec2-6}
-------------

Meta-analysis with allele contrast (A vs. G) showed significant association with both fixed effect (ORAvsG= 1.10; 95%CI= 1.05-1.17; p= \<0.001) and random effect model (ORAvsG= 1.13; 95% CI= 1.02-1.24; p= 0.01) ([Table 2](#T2){ref-type="table"}, [Figure 2](#F2){ref-type="fig"}). There was observed an increased risk of breast cancer using homozygote model (AA vs GG; homozygote model), with both fixed (ORAAvsGG= 1.32; 95%CI= 1.17-1.49; p= \<0.001) and random (ORAAvsGG= 1.38; 95%CI= 1.08-1.76; p=0.009) effect models with high statistical heterogeneity between studies ([Table 2](#T2){ref-type="table"}, [Figure 3](#F3){ref-type="fig"}). Association of mutant heterozygous genotype (GAvs.GG; co-dominant model) was not observed significant with both fixed (ORGAvsGG= 1.03; 95%CI= 0.96-1.11; p= 0.34) and random (ORGAvsGG= 1.03; 95%CI= 0.93-1.14; p= 0.48) effect models. Combined mutant genotypes (AA+GA vs GG; dominant model) showed positive association with breast cancer using fixed (ORAA+GAvsGG= 1.08; 95%CI= 1.01-1.16; p= 0.02)effect model ([Table 2](#T2){ref-type="table"}). Similarly the recessive genotypes model (AA vs. GA+GG) also showed significant strong association with breast cancerusing both fixed (ORAAvsGA+GG= 1.29; 95%CI= 1.15-1.45; p= \<0.001) and random (ORAAvsGA+GG= 1.35; 95%CI= 1.07-1.71; p= 0.01) effect models ([Table 2](#T2){ref-type="table"}, [Figure 4](#F5 F4){ref-type="fig"}).

###### 

Summary Estimates for the Odds Ratio (OR) in Various Allele/Genotype Contrasts, the Significance Level (P Value) of Heterogeneity Test (Q Test), and the I^2^ Metric: Overall Analysis, and Subgroup Analyses.

                             Genetic Contrast            Fixed effect OR (95% CI), p   Random effect OR (95% CI), p   Heterogeneity p-value (Q test)   I^2^ (%)   Publication Bias (p of Egger's test)
  -------------------------- --------------------------- ----------------------------- ------------------------------ -------------------------------- ---------- --------------------------------------
  All                        Allele Contrast (A vs. G)   1.10 (1.05-1.17), \<0.001     1.13 (1.02-1.24), 0.01         \<0.001                          63.71      0.36
  Dominant (AA+AG vs. GG)    1.08 (1.01-1.16), 0.02      1.09 (0.99-1.21), 0.07        0.009                          43.9                             0.61       
  Homozygote (AA vs. GG)     1.32 (1.17-1.49), \<0.001   1.38 (1.08-1.76), 0.009       \<0.001                        68.73                            0.33       
  Co-dominant (GA vs. GG)    1.03 (0.96-1.11), 0.34      1.03 (0.93-1.14), 0.48        0.04                           35.21                            0.87       
  Recessive (GG+GA vs. AA)   1.29 (1.15-1.45), \<0.001   1.35 (1.07-1.71), 0.01        \<0.001                        70.64                            0.27       
  Pre                        Allele Contrast (A vs. G)   1.11 (1.00-1.23), 0.03        1.17 (1.01-1.36), 0.03         0.09                             38.27      0.05
  Dominant (AA+AG vs. GG)    1.06 (0.93-1.22), 0.36      1.06 (0.92-1.22), 0.36        0.45                           0.00                             0.02       
  Homozygote (AA vs. GG)     1.38 (1.09-1.75), 0.006     1.53 (0.98-2.40), 0.05        0.004                          61.58                            0.29       
  Co-dominant (GA vs. GG)    1.00 (0.86-1.15), 0.96      1.02 (0.86-1.21), 0.77        0.34                           10.84                            0.13       
  Recessive (GG+GA vs. AA)   1.38 (1.11-1.71), 0.003     1.48 (0.95-2.29), 0.07        \<0.001                        66.84                            0.45       
  Post                       Allele Contrast (A vs. G)   1.04 (0.92-1.18), 0.46        1.04 (0.90-1.21), 0.53         0.25                             20.18      0.58
  Dominant (AA+AG vs. GG)    1.04 (0.88-1.22), 0.62      1.04 (0.86-1.25), 0.65        0.32                           13.04                            0.61       
  Homozygote (AA vs. GG)     1.11 (0.83-1.47), 0.47      1.05 (0.65-1.70), 0.81        0.03                           49.89                            0.53       
  Co-dominant (GA vs. GG)    1.01 (0.85-1.21), 0.83      1.01 (0.81-1.26), 0.88        0.2                            26.09                            0.77       
  Recessive (GG+GA vs. AA)   1.11 (0.85-1.44), 0.43      1.07 (0.68-1.67), 0.76        0.02                           52.54                            0.59       
  Mixed                      Allele Contrast (A vs. G)   1.13 (1.05-1.21), \<0.001     1.14 (0.98-1.32), 0.08         \<0.001                          73.06      0.58
  Dominant (AA+AG vs. GG)    1.11 (1.01-1.22), 0.02      1.10 (0.95-1.29), 0.19        0.004                          56.41                            0.61       
  Homozygote (AA vs. GG)     1.37 (1.16-1.62), \<0.001   1.40 (1.01-1.95), 0.04        \<0.001                        69.87                            0.53       
  Co-dominant (GA vs. GG)    1.06 (0.96-1.17), 0.23      1.04 (0.91-1.18), 0.52        0.1                            32.85                            0.77       
  Recessive (GG+GA vs. AA)   1.31 (1.12-1.54), \<0.001   1.35 (1.00-1.83), 0.04        \<0.001                        67.98                            0.59       
  Hospital based             Allele Contrast (A vs. G)   1.17 (1.07-1.27), \<0.001     1.18 (1.01-1.36), 0.02         \<0.001                          65.22      0.77
  Dominant (AA+AG vs. GG)    1.19 (1.07-1.32), 0.001     1.18 (1.00-1.40), 0.04        0.01                           52.18                            0.86       
  Homozygote (AA vs. GG)     1.38 (1.14-1.68), 0.001     1.44 (0.93-2.24), 0.09        \<0.001                        75.07                            0.68       
  Co-dominant (GA vs. GG)    1.15 (1.03-1.29), 0.01      1.13 (0.95-1.35), 0.15        0.01                           52.21                            0.58       
  Recessive (GG+GA vs. AA)   1.30 (1.08-1.57), 0.005     1.37 (0.89-2.11), 0.14        \<0.001                        75.94                            0.59       
  Population based           Allele Contrast (A vs. G)   1.02 (0.94-1.10), 0.59        1.02 (0.91-1.14), 0.71         0.03                             48.22      0.87
  Dominant (AA+AG vs. GG)    0.97 (0.88-1.07), 0.60      0.97 (0.87-1.08), 0.64        0.39                           5.11                             0.85       
  Homozygote (AA vs. GG)     1.15 (0.97-1.36), 0.09      1.15 (0.87-1.51), 0.30        0.01                           53.52                            0.99       
  Co-dominant (GA vs. GG)    0.94 (0.84-1.04), 0.25      0.94 (0.84-1.04), 0.25        0.62                           0.00                             0.71       
  Recessive (GG+GA vs. AA)   1.17 (0.99-1.37), 0.05      1.18 (0.89-1.55), 0.23        0.005                          60.11                            0.87       
  Not reported               Allele Contrast (A vs. G)   1.49 (1.20-1.85), \<0.001     1.49 (1.08-2.05), 0.13         0.11                             53.64      NA
  Dominant (AA+AG vs. GG)    1.36 (1.01-1.83), 0.03      1.36 (1.01-1.83), 0.03        0.52                           0.00                             NA         
  Homozygote (AA vs. GG)     2.66 (1.66-4.25), \<0.001   2.63 (1.32-5.22), 0.006       0.13                           49.87                            NA         
  Co-dominant (GA vs. GG)    1.05 (0.77-1.45), 0.72      1.05 (0.77-1.45), 0.72        0.66                           0.00                             NA         
  Recessive (GG+GA vs. AA)   2.36 (1.54-3.61), \<0.001   2.45 (1.08-5.56), 0.03        0.03                           69.44                            NA         

![Random Effect Forest Plot of Allele Contrast Model (A vs. G) of *COMT G472A* Polymorphism](APJCP-18-1243-g002){#F2}
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Subgroup analysis {#sec2-7}
-----------------

Subgroup analysis were done on the basis of source of control (i.e. hospital based or population based) and status of menopause (i.e. premenopause and postmenopause). In total 26 studies, in 12 studies controls were selected from hospital and in remaining studies control samples were selected from population. In allele contrast meta-analysis with twelve studied of hospital based, showed significant association between COMT Val158Met polymorphism and breast cancer (ORAvsG = 1.18; 95%CI= 1.01-1.36; p= 0.02; I2=65.2%) and meta-analysis of eleven population based studies did not show any association(ORAvsG = 1.02; 95%CI= 0.94-1.10; p= 0.59; I^2^=48.22%). In three studies details of control samples were not given.

In eleven studies, subject were of premenopausal state, allele contrast meta-analysis showed meager association between COMT Val158Met polymorphism and breast cancer (ORAvsG= 1.11; 95%CI= 1.00-1.23; p= 0.03; I^2^= 38.27%), but meta-analysis of ten studies analysed postmenopausal subject did not show any association (ORAvsG= 1.04; 95%CI= 0.92-1.18; p= 0.46; I^2^= 20.18%). In four studies menopausal state of subjects were not mentioned.

Sensitivity analysis {#sec2-8}
--------------------

In allele contrast meta-analysis, sensitivity analysis performed by exclusion of studies in which control population was not in HWE. Exclusion of two studies not in HWE (Yim et al., 2001;Sazciet al., 2004) did not affect heterogeneity but increased odds ratio (OR= 1.12; 95%CI= 1.01-1.23; p= 0.02).

Publication bias {#sec2-9}
----------------

Publication bias was absent in all five genetic models and P value of Egger's test was greater than 0.05 (A vs G, p= 0.36; AG vs GG, p= 0.87; AA vs GG, p= 0.33; AA+AG vs GG, p= 0.61; AA vs AG+GG, p= 0.27). Funnel plots using standard error and precision were also symmetrical ([Figure 5](#F5){ref-type="fig"}).

![Funnel Plots a-f, a. Precision by log odds ratio for additive model; b, standard error by log odds ratio for additive model; c, precision by log odds ratio for homozygote model; d, standard error by log odds ratio for homozygote model; e, precision by log odds ratio for recessive model; f, standard error by log odds ratio for recessive model.](APJCP-18-1243-g005){#F5}

Discussion {#sec1-4}
==========

Present meta-analysis of the association of the COMT Val158Met polymorphism with BC investigated 5,971 BC patients and 7,253 controls from 26 Asian case--control studies. The overall meta-analysis detected significant genetic association between the COMT Val158Met polymorphism and BC in Asian population. Five meta-analysis studies have been published so far on COMT Val 158Met polymorphism and breast cancer risk (Ding et al.,2010; He et al., 2012; Qin et al., 2012; Li et al., 2014; Wan et al., 2014) and reported no significant association. In all these five meta-analyses, information of Asian population is incomplete, hence present meta-analysis was conducted on case-control reports on Asian population and results suggested that the COMT Val158Met polymorphism is a risk factor for breast cancer development in the Asian population.

The COMT enzyme catalyzes the transfer of a methyl group from the S-adenosyl-L-methionine to the m-hydroxy group of catechol compounds, rendering the catechol estrogens more water soluble and enhancing excretion from the body (Service,1998; Ahsan et al., 2004). Several studies suggested protective role to COMT higher activity isoform, which protect reactive oxygen induced DNA damage, that are produced by estrogen oxidation(Onay et al., 2008). Prolonged exposure to estrogen is a risk factor for breast carcinoma (Hoffman et al., 1979; Amin et al., 1983; Lajin et al., 2013). Catechol estrogen metabolitesare genotoxic andcapable of initiating mammary tumors through their reactive metabolites by formation of depurinatingDNA adducts which are capable of creating de novo oncogenic mutations (Jan et al., 1998; Ahsan et al., 2004; Lajin et al., 2013).

Meta-analysis is a powerful statistical tool for analyzing cumulative data of case-control studies wherein the individual sample sizes are small and potentially investigates a large number of individuals and can estimate the effect of a genetic factor on the risk of the disease (Liwei et al., 2009; Li et al., 2013; Rai et al., 2014; Kumar et al., 2015). Several meta-analyses investigating the association of COMT Val158Met polymorphism with various disease/disorders have been published, like-attention-deficit/hyperactivity disorder (Sun et al., 2014), schizophrenia (Munafo et al., 2005), prostate cancer (Xiao et al., 2013; Zou et al., 2013) etc.

The present meta-analysis has few limitations like-(i) meta-analysis based on unadjusted data, (ii)there is marked heterogeneity among studies, and (iii)owing to the lack of information, gene-gene interactions were not done.

In conclusion, the results of present meta-analysis support significant association between the COMT Val158Met polymorphism and breast cancer risk in Asian population. The results should be interpreted cautiously due to presence of high heterogeneity. In future, case control studies from different ethnic populations with larger sample sizes should be carried out to confirm the association between COMT Val158Met polymorphism and breast cancer. Further, gene-gene and gene-environmental interactions should also be investigated.
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